0001764013-23-000006.txt : 20230113
0001764013-23-000006.hdr.sgml : 20230113
20230113081329
ACCESSION NUMBER: 0001764013-23-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230111
FILED AS OF DATE: 20230113
DATE AS OF CHANGE: 20230113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Macias William L.
CENTRAL INDEX KEY: 0001864280
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 23527317
MAIL ADDRESS:
STREET 1: C/O IMMUNOVANT, INC.
STREET 2: 320 WEST 37TH STREET, 6TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wf-form4_167361559332752.xml
FORM 4
X0306
4
2023-01-11
0
0001764013
Immunovant, Inc.
IMVT
0001864280
Macias William L.
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
0
1
0
0
Chief Medical Officer
Common Stock
2023-01-11
4
S
0
120
15.11
D
307981
D
Common Stock
2023-01-11
4
S
0
44448
16.75
D
263533
D
On November 5, 2021, the holder was granted 112,108 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 9, 2021. These RSUs vested in their entirety on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs and do not represent a discretionary sale by the holder.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 - $15.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for William L. Macias
2023-01-13